Arrowhead Pharmaceuticals’ plozasiran (Redemplo) delivered “best-case scenario” results in two late-stage trials aimed at expanding use in severe hypertriglyceridemia, the company said Wednesday. In the year-long studies in adults with severe hypertriglyceridemia, median triglycerides fell 79% and 81% with the under-the-skin once-every-three-month RNA interference therapy versus about 27% with placebo, Arrowhead reported. The program also assessed acute pancreatitis, a major risk driven by very high triglyceride levels. A pooled analysis showed acute pancreatitis events dropped 78% versus control arms. Arrowhead said safety and tolerability remained favorable, with no clinically meaningful liver-enzyme deterioration, no cases of abnormally low platelets, and no hypersensitivity signals. Arrowhead plans to formally ask U.S. regulators to add severe hypertriglyceridemia to the Redemplo label before year-end, positioning the genetic medicine for broader adoption beyond its current rare-disease indication.